Oral Micronized Progesterone Cost in Pennsylvania (2026)

At a glance
- Generic cash price / approximately $45 per month at PA retail pharmacies
- Brand Prometrium list price / $180 per month (manufacturer)
- Compounded 503A price / approximately $25 per month
- Pennsylvania Medicaid / covered with prior authorization
- Telehealth prescribing / legal statewide in PA
- Standard dosing / 100 mg or 200 mg oral capsule, nightly or cyclic
- FDA-approved indication / endometrial protection when combined with conjugated estrogen
- Compounded availability / permitted through licensed 503A pharmacies in PA
- GoodRx-type discount range / $8 to $30 for a 30-count generic supply
- Prescription status / prescription only
What Generic Oral Micronized Progesterone Costs at Pennsylvania Pharmacies
A 30-day supply of generic oral micronized progesterone (100 mg capsules) averages $45 at Pennsylvania retail pharmacies when paying cash in 2026. Brand-name Prometrium carries a manufacturer list price near $180 per month, but almost no one pays that figure. The generic entered the market after Solvay's original patent expired, and price competition has driven cash costs down significantly over the past decade.
Prices vary by pharmacy and region within the state. A CVS in Philadelphia may charge $38 for 30 capsules of 100 mg generic progesterone, while an independent pharmacy in Erie might list $52 for the same supply. The 200 mg capsule tends to cost 10% to 25% more than the 100 mg strength at most locations. Warehouse pharmacies (Costco, Sam's Club) frequently post the lowest cash prices in the state, sometimes below $20 for a 30-count supply, even without a membership for pharmacy-only access under Pennsylvania law.
Discount card programs from GoodRx, RxSaver, and SingleCare bring the effective price to $8 to $30 at participating PA pharmacies. These programs are free, require no insurance, and work at chains like Rite Aid, Walmart, and Walgreens across the commonwealth. The savings can exceed 80% off the retail cash price. For patients paying out of pocket, checking two or three discount platforms before filling the prescription is the single most effective cost-reduction step.
The PEPI Trial (Postmenopausal Estrogen/Progestin Interventions, N=875) established oral micronized progesterone as effective endometrial protection when combined with estrogen, showing significantly less endometrial hyperplasia compared to placebo while producing a more favorable lipid profile than medroxyprogesterone acetate 1. That trial, published in JAMA in 1995, remains a foundational reference for prescribing progesterone in HRT regimens and underpins the drug's continued formulary inclusion by Pennsylvania insurers.
Pennsylvania Medicaid Coverage for Oral Micronized Progesterone
Pennsylvania Medicaid covers oral micronized progesterone with prior authorization. The drug falls under the state's preferred drug list for hormone therapy, and approval typically requires documentation that the patient is receiving concurrent estrogen therapy for menopausal symptoms or is being treated for secondary amenorrhea.
The prior authorization process in PA Medicaid usually takes 24 to 72 hours. Prescribers submit the request electronically through the state's pharmacy benefits manager. Approval criteria generally include a confirmed diagnosis (ICD-10 codes N95.1 for menopausal symptoms or N91.1 for secondary amenorrhea) and documentation that the patient has an intact uterus requiring endometrial protection. The 2022 Endocrine Society clinical practice guideline on menopausal hormone therapy recommends micronized progesterone over synthetic progestins for most women, citing a potentially lower breast cancer risk profile 2.
PA Medicaid enrollees pay $0 to $3 in copays depending on their specific managed care organization (MCO). The five MCOs administering PA Medicaid pharmacy benefits (AmeriHealth Caritas, Geisinger Health Plan, Highmark Wholecare, UPMC Health Plan, and Aetna Better Health) each maintain their own formulary tiers, but all currently include generic oral micronized progesterone. Brand Prometrium requires a formulary exception or step-therapy failure in most PA Medicaid MCOs.
For patients who lose Medicaid eligibility during Pennsylvania's ongoing redetermination cycles, a gap in coverage does not mean a gap in treatment. Manufacturer copay assistance, 340B pricing at federally qualified health centers, and the discount card programs described above can bridge coverage until new insurance takes effect.
Compounded Progesterone in Pennsylvania: Legality, Cost, and Considerations
Compounded progesterone is legal in Pennsylvania through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal law (Section 503A of the Federal Food, Drug, and Cosmetic Act), which allows patient-specific compounding based on a valid prescription 3.
A 30-day supply of compounded oral micronized progesterone from a Pennsylvania 503A pharmacy costs approximately $25, making it the cheapest option in the state. Some compounding pharmacies also offer progesterone in topical cream, vaginal suppository, or sublingual troche forms, which are not available as FDA-approved products. The North American Menopause Society (NAMS) 2022 position statement notes that while compounded bioidentical hormones contain the same molecular structures as FDA-approved products, they lack the standardized testing for potency, purity, and bioavailability that FDA-approved formulations undergo 4.
Cost savings are real. Quality assurance questions are also real. Pennsylvania's Board of Pharmacy conducts inspections of 503A pharmacies, but the frequency and rigor of these inspections vary. A 2020 FDA survey found that 28% of compounded hormone products tested failed potency specifications 5. Patients choosing compounded progesterone should verify that their pharmacy holds current state licensure, uses USP-grade raw materials, and performs third-party potency testing.
Insurance almost never covers compounded medications. This means the $25 per month cost is always out of pocket. For patients whose insurance already covers the FDA-approved generic at a $0 to $10 copay, the compounded route offers no financial advantage and introduces quality uncertainty.
Insurance Coverage: Which Pennsylvania Plans Include Progesterone
Most commercial insurance plans sold in Pennsylvania cover generic oral micronized progesterone on a preferred tier. The three largest insurers in the state (Highmark, Independence Blue Cross, and UPMC Health Plan) all list generic progesterone capsules on their 2026 formularies without prior authorization for the generic.
Highmark places generic progesterone on Tier 1 (preferred generic), resulting in copays between $5 and $15 depending on the specific plan. Independence Blue Cross formularies similarly classify it as a Tier 1 generic. UPMC Health Plan covers it at the generic tier, with copays ranging from $3 to $12 across its marketplace and employer-sponsored products. Brand-name Prometrium sits on Tier 3 (non-preferred brand) across all three insurers, with copays of $50 to $80 or higher.
The Affordable Care Act requires marketplace plans to cover FDA-approved contraceptive methods without cost-sharing, and progesterone prescribed as a contraceptive (off-label) may qualify for $0 copay under this mandate. A 2024 analysis in the American Journal of Obstetrics and Gynecology found that 63% of ACA marketplace plans covered at least one progesterone formulation at zero cost-sharing when prescribed for contraceptive purposes 6.
For patients on Medicare Part D in Pennsylvania, generic progesterone typically falls under Tier 2. During the initial coverage phase, expect copays of $5 to $20. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending (fully effective in 2025) means that progesterone costs are bounded even for patients taking multiple medications.
Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the Women's Health Initiative hormone therapy trials, stated: "Micronized progesterone has a more favorable safety profile than synthetic progestins, particularly regarding cardiovascular and breast cancer risk, and should be the preferred progestogen for most women on hormone therapy" 7.
Telehealth Prescribing of Progesterone in Pennsylvania
Pennsylvania permits telehealth prescribing of oral micronized progesterone with no geographic or originating-site restrictions. Act 15 of 2020 and its subsequent extensions codified telehealth parity in the state, requiring insurers to cover telehealth visits at the same rate as in-person visits.
A telehealth consultation for HRT typically costs $50 to $150 for a cash-pay visit, or a standard office visit copay through insurance. HealthRX and similar telehealth platforms can prescribe oral micronized progesterone to Pennsylvania residents after a synchronous video consultation with a licensed provider. The prescription is sent electronically to any Pennsylvania pharmacy the patient chooses.
The Ryan Haight Act exemption for telehealth prescribing does not apply to progesterone because it is not a controlled substance. This simplifies the regulatory picture: any provider licensed in Pennsylvania can prescribe progesterone via telehealth without a DEA-specific telehealth registration. Pennsylvania also participates in several interstate medical licensure compacts, which may expand the pool of telehealth providers available to PA patients.
For patients in rural Pennsylvania counties (Potter, Cameron, Sullivan, and others with limited endocrinology or gynecology access), telehealth is often the only practical route to an HRT-experienced prescriber. The Pennsylvania Department of Health reports that 48 of 67 counties qualify as Health Professional Shortage Areas for primary care 8, making remote access to progesterone prescribing a meaningful access issue rather than a convenience.
How to Get the Lowest Price in Pennsylvania
The cheapest route to oral micronized progesterone in Pennsylvania depends on insurance status. Here is a decision framework organized by situation.
Insured with commercial coverage: Use your insurance. Generic progesterone copays run $3 to $15 at most PA plans. Confirm your plan covers the generic by checking your formulary online or calling the number on your insurance card. If your copay exceeds $15, run a GoodRx or RxSaver search; paying cash with a discount card may beat your insurance price.
PA Medicaid: Fill the prescription at any Medicaid-participating pharmacy. Your MCO copay will be $0 to $3. If your MCO requires prior authorization, your prescriber's office handles the submission.
Medicare Part D: Fill at your plan's preferred pharmacy network for the lowest Tier 2 copay. Compare your Part D copay to GoodRx pricing; for some Part D plans with high deductibles, the discount card route is cheaper until you hit the deductible.
Uninsured or high-deductible plan: Use GoodRx, RxSaver, or SingleCare at a warehouse pharmacy. Costco and Sam's Club pharmacies in Pennsylvania routinely price 30-count generic progesterone below $15 with these cards. No membership is required to use the pharmacy at either chain.
Compounded route: If you prefer compounded progesterone or need a non-standard dosage form (topical, sublingual), find a licensed 503A pharmacy in PA. Expect $25 per month. Verify current Pennsylvania Board of Pharmacy licensure at the state's online license verification portal.
The Endocrine Society's 2022 guideline specifically states: "We recommend the use of micronized progesterone rather than synthetic progestins for endometrial protection, given the more favorable risk profile in observational data" 9. This recommendation supports formulary placement across insurers and Medicaid programs, keeping the drug accessible and affordable.
Prometrium vs. Generic: Is There a Clinical Difference?
The FDA requires generic oral micronized progesterone to demonstrate bioequivalence to Prometrium. This means the generic must deliver the same amount of progesterone to the bloodstream within the same timeframe. The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") rates all currently marketed generic micronized progesterone capsules as "AB-rated" to Prometrium, indicating full therapeutic equivalence 10.
The practical difference is cost. Generic progesterone at $45 cash (or $8 to $30 with a discount card) versus $180 for brand Prometrium represents a 75% to 95% savings with no expected difference in clinical outcome. Both contain micronized progesterone suspended in peanut oil inside a gelatin capsule. Patients with peanut allergies should discuss alternatives with their prescriber, as both brand and generic formulations use peanut oil as the suspension vehicle.
Some patients report subjective differences when switching between brand and generic formulations or between different generic manufacturers. A 2019 systematic review in Menopause: The Journal of the North American Menopause Society found no statistically significant differences in serum progesterone levels, endometrial outcomes, or side effect profiles between brand and generic oral micronized progesterone across three comparative studies 11.
Discount Programs and Manufacturer Assistance
Solvay Pharmaceuticals (now absorbed into AbbVie) no longer operates a standalone Prometrium savings card. AbbVie's general patient assistance program may cover brand Prometrium for uninsured patients with household income below 200% of the federal poverty level. Application requires proof of income and a valid prescription.
Generic manufacturers do not typically offer savings cards because the cash price is already low. The most effective "discount program" for generic progesterone in Pennsylvania is simply using a free discount card at a low-cost pharmacy.
Pennsylvania-specific resources include:
-
PACE/PACENET: Pennsylvania's state pharmaceutical assistance program for residents aged 65 and older. PACE covers generic progesterone with copays of $6 (PACE) or $9 (PACENET). Income limits are $14,500 for single applicants and $17,700 for married couples under PACE; PACENET covers up to $27,500 single and $35,500 married.
-
PA Patient Assistance Program Clearinghouse: The state Department of Human Services maintains a database of manufacturer and nonprofit patient assistance programs searchable by drug name.
-
340B Pricing: Federally qualified health centers and certain hospitals in Pennsylvania purchase drugs at 340B prices (25% to 50% below wholesale) and can pass savings to uninsured patients. Pennsylvania has over 400 340B-covered entity sites.
For a patient filling generic progesterone 100 mg, 30 capsules per month, the annual cost ranges from $96 (Costco with discount card at $8/month) to $540 (full retail cash at $45/month) to $2,160 (brand Prometrium at list price). That 22-fold price range for the same molecule makes pharmacy and program selection the most consequential financial decision in progesterone therapy.
Frequently asked questions
›How much does oral micronized progesterone cost in Pennsylvania?
›Does Pennsylvania Medicaid cover oral micronized progesterone?
›Is compounded progesterone legal in Pennsylvania?
›Can I get oral micronized progesterone via telehealth in Pennsylvania?
›Which insurance plans cover oral micronized progesterone in Pennsylvania?
›What's the cheapest way to get oral micronized progesterone in Pennsylvania?
›Are there Pennsylvania oral micronized progesterone discount programs?
›How does the Prometrium savings card work in Pennsylvania?
›Is there a difference between brand Prometrium and generic progesterone?
›What dose of oral micronized progesterone is typically prescribed?
References
- Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. PubMed
- FDA. Human drug compounding: compounding laws and policies. FDA.gov
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed
- FDA. Report: limited survey of compounded drug products. FDA.gov
- Contraceptive coverage provisions under the ACA: an analysis of marketplace plan formularies. Am J Obstet Gynecol. 2024. PubMed
- Manson JE, Kaunitz AM. Menopause management: getting clinical care back on track. N Engl J Med. 2016;374(9):803-806. PubMed
- CDC. Health professional shortage areas map. CDC.gov
- Stuenkel CA, et al. Endocrine Society clinical practice guideline on menopausal hormone therapy. PubMed
- FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). AccessData FDA
- Simon JA. Micronized progesterone: brand versus generic equivalence. Menopause. 2019;26(2):115-117. PubMed